Arecor Therapeutics plc
AREC.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £16,424 | £27,753 | £36,752 | £55,893 |
| - Cash | £1,867 | £3,239 | £2,529 | £5,093 |
| + Debt | £173 | £232 | £280 | £338 |
| Enterprise Value | £14,730 | £24,746 | £34,503 | £51,138 |
| Revenue | £2,003 | £3,058 | £1,995 | £2,904 |
| % Growth | -34.5% | 53.3% | -31.3% | – |
| Gross Profit | £328 | -£672 | £2,215 | £3,205 |
| % Margin | 16.4% | -22% | 111% | 110.4% |
| EBITDA | -£2,421 | -£5,597 | -£4,553 | -£4,073 |
| % Margin | -120.9% | -183% | -228.2% | -140.2% |
| Net Income | -£2,508 | -£5,596 | -£4,640 | -£4,026 |
| % Margin | -125.2% | -183% | -232.6% | -138.6% |
| EPS Diluted | -0.066 | -0.15 | -0.15 | -0.13 |
| % Growth | 55.7% | 0% | -15.4% | – |
| Operating Cash Flow | -£1,143 | -£4,946 | -£4,163 | -£1,421 |
| Capital Expenditures | -£98 | -£8 | -£15 | -£78 |
| Free Cash Flow | -£1,241 | -£4,954 | -£4,178 | -£1,499 |